Outcomes of immunosuppression minimization and withdrawal early after liver transplantation

Abraham Shaked, Michele R. DesMarais, Heather Kopetskie, Sandy Feng, Jeffrey D. Punch, Josh Levitsky, Jorge Reyes, Goran B. Klintmalm, Anthony J. Demetris, Bryna E. Burrell, Allison Priore, Nancy D. Bridges, Peter H. Sayre

Research output: Contribution to journalArticle

Abstract

The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease. Of 275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1- to 2-years posttransplant. Randomization eligibility criteria included stable immunosuppression monotherapy; adequate liver and kidney function; ≤Stage 2 Ishak fibrosis; and absence of rejection on biopsy. Immunosuppression withdrawal followed an 8-step reduction algorithm with ≥8 weeks per level. Fifty-two of 77 subjects (67.5%) reduced to ≤50% of baseline dose, and 10 of 77 (13.0%) discontinued all immunosuppression for ≥1 year. Acute rejection and/or abnormal liver tests were treated with increased immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. The composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3; or >25% decrease in glomerular filtration rate within 24 months of randomization) occurred in 12 of 66 (18%) and 4 of 13 (31%) subjects in the withdrawal and maintenance groups. Early immunosuppression minimization is feasible in selected liver recipients, while complete withdrawal is successful in only a small proportion. The composite end point comparison was inconclusive for noninferiority of the withdrawal to the maintenance group.

Original languageEnglish (US)
Pages (from-to)1397-1409
Number of pages13
JournalAmerican Journal of Transplantation
Volume19
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Liver Transplantation
Immunosuppression
Liver
Maintenance
Random Allocation
Immune Tolerance
Opportunistic Infections
Methylprednisolone
Hepatitis C
Coinfection
Glomerular Filtration Rate
Liver Diseases
Fibrosis
Transplantation
Transplants
Kidney
Biopsy
Neoplasms

Keywords

  • clinical research/practice
  • clinical trial
  • immunosuppression/immune modulation
  • immunosuppressive regimens - minimization/withdrawal
  • infection and infectious agents - viral: hepatitis C
  • liver transplantation/hepatology
  • tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Shaked, A., DesMarais, M. R., Kopetskie, H., Feng, S., Punch, J. D., Levitsky, J., ... Sayre, P. H. (2019). Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. American Journal of Transplantation, 19(5), 1397-1409. https://doi.org/10.1111/ajt.15205
Shaked, Abraham ; DesMarais, Michele R. ; Kopetskie, Heather ; Feng, Sandy ; Punch, Jeffrey D. ; Levitsky, Josh ; Reyes, Jorge ; Klintmalm, Goran B. ; Demetris, Anthony J. ; Burrell, Bryna E. ; Priore, Allison ; Bridges, Nancy D. ; Sayre, Peter H. / Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. In: American Journal of Transplantation. 2019 ; Vol. 19, No. 5. pp. 1397-1409.
@article{b2210f7e1ffb4d2c84f2502f65061e1a,
title = "Outcomes of immunosuppression minimization and withdrawal early after liver transplantation",
abstract = "The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease. Of 275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1- to 2-years posttransplant. Randomization eligibility criteria included stable immunosuppression monotherapy; adequate liver and kidney function; ≤Stage 2 Ishak fibrosis; and absence of rejection on biopsy. Immunosuppression withdrawal followed an 8-step reduction algorithm with ≥8 weeks per level. Fifty-two of 77 subjects (67.5{\%}) reduced to ≤50{\%} of baseline dose, and 10 of 77 (13.0{\%}) discontinued all immunosuppression for ≥1 year. Acute rejection and/or abnormal liver tests were treated with increased immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. The composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3; or >25{\%} decrease in glomerular filtration rate within 24 months of randomization) occurred in 12 of 66 (18{\%}) and 4 of 13 (31{\%}) subjects in the withdrawal and maintenance groups. Early immunosuppression minimization is feasible in selected liver recipients, while complete withdrawal is successful in only a small proportion. The composite end point comparison was inconclusive for noninferiority of the withdrawal to the maintenance group.",
keywords = "clinical research/practice, clinical trial, immunosuppression/immune modulation, immunosuppressive regimens - minimization/withdrawal, infection and infectious agents - viral: hepatitis C, liver transplantation/hepatology, tolerance",
author = "Abraham Shaked and DesMarais, {Michele R.} and Heather Kopetskie and Sandy Feng and Punch, {Jeffrey D.} and Josh Levitsky and Jorge Reyes and Klintmalm, {Goran B.} and Demetris, {Anthony J.} and Burrell, {Bryna E.} and Allison Priore and Bridges, {Nancy D.} and Sayre, {Peter H.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/ajt.15205",
language = "English (US)",
volume = "19",
pages = "1397--1409",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

Shaked, A, DesMarais, MR, Kopetskie, H, Feng, S, Punch, JD, Levitsky, J, Reyes, J, Klintmalm, GB, Demetris, AJ, Burrell, BE, Priore, A, Bridges, ND & Sayre, PH 2019, 'Outcomes of immunosuppression minimization and withdrawal early after liver transplantation', American Journal of Transplantation, vol. 19, no. 5, pp. 1397-1409. https://doi.org/10.1111/ajt.15205

Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. / Shaked, Abraham; DesMarais, Michele R.; Kopetskie, Heather; Feng, Sandy; Punch, Jeffrey D.; Levitsky, Josh; Reyes, Jorge; Klintmalm, Goran B.; Demetris, Anthony J.; Burrell, Bryna E.; Priore, Allison; Bridges, Nancy D.; Sayre, Peter H.

In: American Journal of Transplantation, Vol. 19, No. 5, 01.05.2019, p. 1397-1409.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcomes of immunosuppression minimization and withdrawal early after liver transplantation

AU - Shaked, Abraham

AU - DesMarais, Michele R.

AU - Kopetskie, Heather

AU - Feng, Sandy

AU - Punch, Jeffrey D.

AU - Levitsky, Josh

AU - Reyes, Jorge

AU - Klintmalm, Goran B.

AU - Demetris, Anthony J.

AU - Burrell, Bryna E.

AU - Priore, Allison

AU - Bridges, Nancy D.

AU - Sayre, Peter H.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease. Of 275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1- to 2-years posttransplant. Randomization eligibility criteria included stable immunosuppression monotherapy; adequate liver and kidney function; ≤Stage 2 Ishak fibrosis; and absence of rejection on biopsy. Immunosuppression withdrawal followed an 8-step reduction algorithm with ≥8 weeks per level. Fifty-two of 77 subjects (67.5%) reduced to ≤50% of baseline dose, and 10 of 77 (13.0%) discontinued all immunosuppression for ≥1 year. Acute rejection and/or abnormal liver tests were treated with increased immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. The composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3; or >25% decrease in glomerular filtration rate within 24 months of randomization) occurred in 12 of 66 (18%) and 4 of 13 (31%) subjects in the withdrawal and maintenance groups. Early immunosuppression minimization is feasible in selected liver recipients, while complete withdrawal is successful in only a small proportion. The composite end point comparison was inconclusive for noninferiority of the withdrawal to the maintenance group.

AB - The Immune Tolerance Network ITN030ST A-WISH assessed immunosuppression withdrawal in liver transplant recipients with hepatitis C or nonimmune nonviral liver disease. Of 275 recipients enrolled before transplantation, 95 were randomly assigned 4:1 to withdrawal (n = 77) or maintenance (n = 18) 1- to 2-years posttransplant. Randomization eligibility criteria included stable immunosuppression monotherapy; adequate liver and kidney function; ≤Stage 2 Ishak fibrosis; and absence of rejection on biopsy. Immunosuppression withdrawal followed an 8-step reduction algorithm with ≥8 weeks per level. Fifty-two of 77 subjects (67.5%) reduced to ≤50% of baseline dose, and 10 of 77 (13.0%) discontinued all immunosuppression for ≥1 year. Acute rejection and/or abnormal liver tests were treated with increased immunosuppression; 5 of 32 rejection episodes required a methylprednisolone bolus. The composite end point (death or graft loss; grade 4 secondary malignancy or opportunistic infection; Ishak stage ≥3; or >25% decrease in glomerular filtration rate within 24 months of randomization) occurred in 12 of 66 (18%) and 4 of 13 (31%) subjects in the withdrawal and maintenance groups. Early immunosuppression minimization is feasible in selected liver recipients, while complete withdrawal is successful in only a small proportion. The composite end point comparison was inconclusive for noninferiority of the withdrawal to the maintenance group.

KW - clinical research/practice

KW - clinical trial

KW - immunosuppression/immune modulation

KW - immunosuppressive regimens - minimization/withdrawal

KW - infection and infectious agents - viral: hepatitis C

KW - liver transplantation/hepatology

KW - tolerance

UR - http://www.scopus.com/inward/record.url?scp=85059264647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059264647&partnerID=8YFLogxK

U2 - 10.1111/ajt.15205

DO - 10.1111/ajt.15205

M3 - Article

VL - 19

SP - 1397

EP - 1409

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -